Morgan Stanley Gracell Biotechnologies Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.43 - $10.04 $49,885 - $206,111	-20,529 Reduced 20.81%	78,119 $784,000
Q3 2023 Nov 15, 2023	BUY	$2.83 - $4.9 $210,198 - $363,947	74,275 Added 304.74%	98,648 $284,000
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $682 - $2,858	-471 Reduced 1.9%	24,373 $92,000
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $4,588 - $6,372	2,549 Added 11.43%	24,844 $46,000
Q4 2022 Feb 14, 2023	SELL	$2.08 - $3.96 $409,371 - $779,379	-196,813 Reduced 89.82%	22,295 $51,000

Q3 2022 Nov 14, 2022	SELL	$2.08 - $5.15 $686,248 - $1.7 Million	-329,927 Reduced 60.09%	219,108 $705,000
Q2 2022 Oct 27, 2022	SELL	$1.95 - $5.5 $153,578 - $433,169	-78,758 Reduced 12.55%	549,035 $3.02 Million
Q2 2022 Aug 15, 2022	SELL	$1.95 - $5.5 $153,578 - $433,169	-78,758 Reduced 12.55%	549,035 $3.02 Million
Q1 2022 Oct 27, 2022	BUY	$1.83 - $5.52 $144,127 - $434,744	78,758 Added 14.34%	627,793 $1.46 Million
Q1 2022 May 13, 2022	BUY	$1.83 - $5.52 $39,641 - $119,574	21,662 Added 3.57%	627,793 $1.46 Million
Q4 2021 Feb 14, 2022	SELL	$5.65 - $14.9 $2.02 Million - $5.32 Million	-357,204 Reduced 37.08%	606,131 $3.66 Million
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $9.55 Million - $14.3 Million	963,335 New	963,335 $13.4 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.